Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 14,125 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Epilepsy, Benign Neonatal
Interventions: Phenobarbital Sodium Injection; Drug
Lead sponsor: NEMA Research, Inc.; Industry
Eligibility: 34 Weeks to 44 Weeks
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Miami, Florida + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 22
States / cities: Chula Vista, California • Fullerton, California • Long Beach, California + 19 more

Conditions: Psoriatic Arthritis
Interventions: NDI-034858, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Palm Desert, California • Upland, California • Hollywood, Florida + 19 more

Conditions: Olmsted Syndrome
Interventions: KM-023, Placebo; Drug
Lead sponsor: Orvida Pharma (formerly Kamari Pharma); Network
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cataract
Interventions: MELT-300, Midazolam alone, Ketamine alone, Placebo; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota

Conditions: Multiple Myeloma
Interventions: TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more

Conditions: Prostate Cancer
Interventions: Enzalutamide, Abiraterone, Placebo for Enzalutamide, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Virginia Beach, Virginia

Conditions: Wound of Skin, Wound Heal, Surgical Wound, Full Thickness Skin Graft Healing
Interventions: 0.25% timolol gel with full-thickness skin grafts, Vaseline dressing; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, Renal Insufficiency
Interventions: Pirtobrutinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 5
States / cities: Anaheim, California • Edgewater, Florida • Miami, Florida + 2 more

Conditions: Psoriasis
Interventions: IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more

Conditions: Pain
Interventions: Oxycodone hydrochloride controlled-release tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Birmingham, Alabama • Paramount, California • Aurora, Colorado + 10 more

Conditions: Rosacea
Interventions: CLS001 (Omiganan), Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more

Conditions: HIV Infections
Interventions: DNA CON-S env, IHV01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Evaluate Web-based Child Safety Intervention Website for Parents
Interventions: Safe Kids Washington, Active Control condition; Other
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions: AV-001 Injection, AV-001 Placebo Injection; Drug
Lead sponsor: Vasomune Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Newport Beach, California • Denver, Colorado • Chicago, Illinois + 3 more

Conditions: Hyperphosphatemia, Chronic Kidney Disease
Interventions: Placebo, Sevelamer carbonate; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 18 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more

Conditions: Down Syndrome
Interventions: ELND005, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Boston, Massachusetts

Conditions: Non-cardiac Surgical, Intensive Care Unit (ICU)
Interventions: Philips Advanced Monitoring Cuff (i.e. AMC); Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Winston-Salem, North Carolina

Conditions: Emergencies, Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus
Interventions: Video teleconsultation, Audio support; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more

Conditions: Autism Spectrum Disorder
Interventions: Oral cannabidiol 100mg/mL, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 17 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Active Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 62
States / cities: Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more

Conditions: Covid19
Interventions: Ampion, Placebo; Biological · Other
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD
Interventions: JZP541, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

Evaluation of an Online Educational Child Injury Prevention Intervention

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

The HIgh-fidelity Hydraulic couPling Upper-arm Cuff Assessment of Limits, Safety, and Effectiveness (HIPULSE) Trial

Simulation Trial of Telemedical Support for Paramedics

CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder